
- Volume 0 0
COMPOUNDING HOTLINE
Q I work as a relief pharmacist for a chain drugstore. Thepharmacists at 2 stores in the chain compound topical formulationsthat contain nystatin powder and other ingredients, indifferent proportions. At one store, the formulation is refrigerated;at the other it is not. Nystatin powder is a refrigerated product.Should both preparations be refrigerated and so labeled oncecompounded?
A Nystatin USP is sometimes referred to as Nystatin forExtemporaneous Compounding of Oral Suspension andhas a specified potency of 5000 units per mg when used in thisfashion. It is distinguished from Nystatin for Oral Suspension,which may contain flavoring, preservatives, and the like; and fromNystatin Topical Powder, which contains nystatin diluted with inertmaterial for use in the treatment of dermatologic conditions.
Nystatin degrades rapidly in the presence of moisture; hencethe admonition to dispense it as dry powder with "Refrigerate"labeling. (Refrigeration slows degradation; humidity in a refrigeratorgenerally is lower than ambient humidity.) The patient "compounds"the nystatin in water at the time of administration. Thematerial degrades to subpotency within ~90 days after the containeris opened. The material reportedly is stable at room temperature(sealed) for ~30 days. When combined with other ingredientsin dry form (Nystatin Topical Powder) or in aqueoussuspension with sugar, the product is stable. Moreover, in an oilin-water emulsion (Nystatin Cream USP) or in an anhydrousbase (Nystatin Ointment USP), the nystatin reportedly is stablefor an extended period. The USP Compounding Monograph<795> discusses stability of compounded products where nostudies are available and no adequate information on which tomake professional judgment can be found. When water is present,the product is assigned a 14-day "beyond-use" date. If theproduct is anhydrous, the beyond-use date is 30 days. One factoraffecting stability, beyond those discussed, is interaction ofingredients in a compounded preparation. The possibility ofincompatibilities should be considered when assigning abeyond-use date and specifying storage conditions.
E-mail your compounding questions [email protected]
Mr. Erickson is director of professional affairs at Gallipot Inc.
Articles in this issue
almost 22 years ago
Training Reinforcementsalmost 22 years ago
Hospice Care: Pharmacotherapy for Comfort Carealmost 22 years ago
Finger Pointing by Doctor and Pharmacist Over Refillsalmost 22 years ago
Pharmacist's Counseling Guide for Obesity Managementalmost 22 years ago
A Gaining Trend: Obesity in the United Statesalmost 22 years ago
Fructose May Lead to Overeatingalmost 22 years ago
Obesity Rates Climb in the Elderlyalmost 22 years ago
Food Regulations Are Proposed Abroadalmost 22 years ago
Weight Loss in Obese Women Improves Lung Functionalmost 22 years ago
Obesity Hinders Sexual Functioning
































































































































